Interim report January – September 2026: Increasing profitability and important strategic progress
Summary by AI BETAClose X
Surgical Science reported Q3 net sales of SEK 260.2 million (−1% vs SEK 263.6m year‑earlier), license revenue SEK 76.0m (29% of sales), gross margin 68%, operating profit SEK 32.0m, net profit SEK 34.1m and EPS SEK 0.67, with operating cash flow SEK 42.5m and cash SEK 674.9m at 30 Sep 2026. For January–September net sales were SEK 750.2m (+4% vs SEK 723.5m), license revenue SEK 228.4m (30% of sales), gross margin 68%, operating profit SEK 87.5m (vs SEK 28.7m year‑ago), net profit SEK 73.6m and EPS SEK 1.44, with operating cash flow SEK 123.1m.
Third quarter 2026 (July – September)
- Net sales amounted to SEK 260.2 (263.6) million, a decrease of 1 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales also decreased by 1 percent.
- License revenue amounted to SEK 76.0 (65.5) million and accounted for 29 (25) percent of net sales.
- The gross margin was 68 (65) percent.
- Operating profit amounted to SEK 32.0 (27.2) million.
- Net profit amounted to SEK 34.1 (20.4) million, corresponding to earnings per share of SEK 0.67 (0.40).
- Cash flow from operating activities amounted to SEK 42.5 (-4.4) million. As at September 30, 2026, cash and cash equivalents amounted to SEK 674.9 (597.4) million.
First nine months of 2026 (January – September)
- Net sales amounted to SEK 750.2 (723.5) million, an increase of 4 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales increased by 5 percent.
- License revenue amounted to SEK 228.4 (208.3) million and accounted for 30 (29) percent of net sales.
- The gross margin was 68 (66) percent.
- Operating profit amounted to SEK 87.5 (28.7) million.
- Net profit amounted to SEK 73.6 (33.6) million, corresponding to earnings per share of SEK 1.44 (0.66).
- Cash flow from operating activities amounted to SEK 123.1 (6.9) million.
Gothenburg, Sweden, November 12, 2026
Surgical Science Sweden AB (publ)
This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/investor-relations/#press-releases
https://surgicalscience.com/aktien/financial-report
This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund